Respiree

News

Health tech Respiree, developer of AI platforms to manage disease progression, has announced the successful closing of an $11.6m Series A financing.

News

The real-time sensor can be used to spot exacerbations of COPD days in advance, says company.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.